Cipla on the block: Who's a better fit and what it means for shareholders?

As per IIFL Securities, Cipla with a dominating market share of 7% and 23% in acute therapies like respiratory and anti-infectives, respectively, would strengthen Torrent's position in these

Web Exclusive Premium

Harshita Singh New Delhi

Listen to This Article

India’s third-largest pharmaceutical company by revenue, Cipla, is up for grabs in a three-way fight between Torrent Pharmaceuticals, Dr. Reddy’s Laboratories (DRL) and private equity (PE) giant Blackstone. 

Analysts say

Also Read

Torrent Pharma gears up to buyout Cipla promoters, approach PE funding

Nifty holding above key DMAs, to make new high on breakout from this hurdle

Cipla Q1 preview: India biz may push profit over 50% QoQ; US sales to drag

JSW Energy scales fresh high on report PE investors eyeing stake in unit

Torrent promoters may pledge stake in power arm to fund Cipla buy

GMR Power wins new contract for smart meters; stock hits 10% upper limit

Amber, FSL, Balaji Amines: 5 smallcap stocks that can fall up to 14%

Ajanta Pharma surges 11% in subdued market on healthy business outlook

This Ashish Kacholia-owned education stock has zoomed over 69% in 3 days

KEC Intl hits new high, gains 11% on winning orders worth Rs 1,012 cr

First Published: Sep 13 2023 | 12:44 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on are available only to BS Premium subscribers.

Register to